# NM_005228.5(EGFR):c.2544G>A (p.Pro848=)

https://sugi.bio/variant/egfr-p-pro848

## Summary

**EGFR p.Pro848= (c.2544G>A)** is classified **Benign/Likely benign** in EGFR (ClinVar, Multiple submitters, 4 submitters; last evaluated 2026-01-19). Ultra-rare (popmax 0.03%, amr); Associated with lung cancer.

**At a glance:** Benign/Likely benign · review: Multiple submitters · rsID rs104886012 · 4 submitters · 3 linked conditions · ultra-rare (popmax 0.03%, amr)

## For patients & families {#patients}

This is a change in the EGFR gene that is classified as benign/likely benign — not considered disease-causing, submitted by 4 submitters, and is linked to lung cancer.

*Reference information, not medical advice, and not a prediction for any individual. A genetic counselor or clinician can interpret what it means for you and your family.*

|  |  |
| --- | --- |
| Clinical trials | 3808 registered for this condition — see ClinicalTrials.gov |

**Support & next steps:** [Find a genetic counselor (NSGC)](https://findageneticcounselor.nsgc.org/).

## Identity {#identity}

| Field | Value |
| --- | --- |
| Gene | [EGFR](https://sugi.bio/atlas/gene/EGFR/) |
| Protein change (HGVS p.) | p.Pro848= |
| Coding change (HGVS c.) | c.2544G>A |
| MANE Select transcript | [NM_005228](https://www.ncbi.nlm.nih.gov/nuccore/NM_005228) |
| dbSNP | [rs104886012](https://www.ncbi.nlm.nih.gov/snp/rs104886012/) |
| Variant type | single nucleotide variant |
| Location | chr7:55191793-55191793 (GRCh38) |
| ClinVar | [VCV132949](https://www.ncbi.nlm.nih.gov/clinvar/variation/132949/) |

**All HGVS expressions:** `LRG_304:g.177762G>A`, `LRG_304t1:c.2544G>A`, `NC_000007.13:g.55259486G>A`, `NC_000007.14:g.55191793G>A`, `NG_007726.3:g.177762G>A`, `NM_001346897.2:c.2409G>A`, `NM_001346898.2:c.2544G>A`, `NM_001346899.2:c.2409G>A`, `NM_001346900.2:c.2385G>A`, `NM_001346941.2:c.1743G>A`, `NM_005228.3:c.2544G>A`, `NM_005228.5:c.2544G>A`

## Computational & population evidence {#evidence}

**Concordance:** Mixed / partial computational evidence (see below).

- **Missense predictors (AlphaMissense/REVEL/SaProt) do not apply** to this variant type — they score amino-acid substitutions only. For non-missense variants the computational signal comes from conservation (below), not from a missing predictor score.
- Conservation: phyloP -10.61, GERP -3.76 — fast-evolving / accelerated position
- CADD: **PHRED 0.309**. No single ClinGen-calibrated threshold exists and the expert panels that use CADD disagree — GUCY2D/AIPL1 require ≥ 20.0 for an untranslated-region variant, ABCA4 ≥ 28.1 for a synonymous or indel variant, the Pulmonary Hypertension panel imports Pejaver 2022's missense-calibrated numbers, and the Antibody Deficiencies panel declines CADD entirely for PIK3CD. CADD v1.7 also incorporates Zoonomia phyloP, so it partly re-expresses the conservation above. *Descriptive; no threshold applied.*
- SpliceAI: **not assessed** — no allele at this position is in our SpliceAI release, either because it lies outside the scored MANE transcript scope or because every allele is below Δ0.2. We cannot tell which, so this claims neither; absence is not evidence against a splicing effect.
- Population frequency (gnomAD v4.1): grpmax **0.03%** (amr) · FAF95 0.0194% · FAF99 0.016% · 18/60,020 in the highest group · 63/1,614,072 alleles overall — ultra-rare (popmax 0.03%, amr).

| Ancestry group | Allele frequency | 1 in |
| --- | --- | --- |
| Admixed American (grpmax) | 0.03% | 3,334 |
| Remaining individuals (not grpmax-eligible) | 0.0112% | 8,929 |
| European (non-Finnish) | 0.00305% | 32,779 |
| African / African-American | 0.00267% | 37,509 |

*Computational predictors are not independent (ClinGen Variant Classification guidance): AlphaMissense (Cheng et al. 2023) carries the ACMG weight for missense and conservation (phyloP/GERP/phastCons) for non-missense; REVEL (Pejaver-2022 calibrated strength bands) and SaProt (Su et al. 2023, structure-aware, ClinVar-independent protein language model, raw LLR) are shown as orthogonal agreement signals, not additive. For frequency, the gnomAD v4.1 grpmax filtering allele frequency (FAF95) is ClinGen's designated BA1/BS1 input (gnomAD v4 guidance v3.0, June 2025); BA1/BS1 thresholds are disease-specific, not a blanket 5%. Predictions, not a clinical determination.*

## Gene constraint & dosage {#gene-context}

**EGFR** population constraint: LOEUF 0.475, pLI 0.98251, missense-Z 3.0635; ClinGen dosage — haploinsufficiency 0, triplosensitivity 0 (0–3 scale). *Lower LOEUF and higher pLI indicate a gene that tolerates loss-of-function poorly; ClinGen dosage is the curated haploinsufficiency call.*

Curated gene–disease validity (ClinGen):

- **non-small cell lung carcinoma** — Definitive (AD)

## Protein context {#protein}

Residue **848** lies in the protein kinase domain.

AlphaFold model confidence (whole protein): pLDDT 76.29, 48% of residues very-high.

**393 experimental structure(s)** (PDB): [1IVO](https://www.rcsb.org/structure/1IVO), [1M14](https://www.rcsb.org/structure/1M14), [1M17](https://www.rcsb.org/structure/1M17), [1MOX](https://www.rcsb.org/structure/1MOX), [1NQL](https://www.rcsb.org/structure/1NQL), [1XKK](https://www.rcsb.org/structure/1XKK) — incl. mutant structure 3IKA.

## What this gene does {#gene-function}

*Describes the biological roles of EGFR (the gene this variant disrupts) — not effects measured for this specific variant. A damaging variant is expected to affect these functions and pathways; the degree depends on the variant.*

**How this variant is thought to act:** EGFR's established molecular role includes chromatin binding. p.Pro848= falls in the protein kinase domain. In Reactome, EGFR is annotated in disease pathway(s) including **Constitutive Signaling by Aberrant PI3K in Cancer**, **Constitutive Signaling by EGFRvIII**.

**Disease mechanism (Reactome):** EGFR loss or alteration is curated in [Constitutive Signaling by Aberrant PI3K in Cancer](https://reactome.org/content/detail/R-HSA-2219530), [Constitutive Signaling by EGFRvIII](https://reactome.org/content/detail/R-HSA-5637810), [Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants](https://reactome.org/content/detail/R-HSA-1236382).

### Pathways affected {#pathways}

EGFR participates in **37 Reactome pathways** (⚕ = disease pathway):

| Pathway (Reactome) | Evidence |
| --- | --- |
| ⚕ [Constitutive Signaling by Aberrant PI3K in Cancer](https://reactome.org/content/detail/R-HSA-2219530) | curated |
| ⚕ [Constitutive Signaling by EGFRvIII](https://reactome.org/content/detail/R-HSA-5637810) | curated |
| ⚕ [Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants](https://reactome.org/content/detail/R-HSA-1236382) | curated |
| ⚕ [HCMV Early Events](https://reactome.org/content/detail/R-HSA-9609690) | curated |
| ⚕ [Inhibition of Signaling by Overexpressed EGFR](https://reactome.org/content/detail/R-HSA-5638303) | curated |
| ⚕ [Respiratory syncytial virus (RSV) attachment and entry](https://reactome.org/content/detail/R-HSA-9820960) | curated |
| ⚕ [Signaling by ERBB2 ECD mutants](https://reactome.org/content/detail/R-HSA-9665348) | curated |
| ⚕ [Signaling by ERBB2 KD Mutants](https://reactome.org/content/detail/R-HSA-9664565) | curated |
| ⚕ [Signaling by ERBB2 TMD/JMD mutants](https://reactome.org/content/detail/R-HSA-9665686) | curated |
| [Cargo recognition for clathrin-mediated endocytosis](https://reactome.org/content/detail/R-HSA-8856825) | curated |
| [Clathrin-mediated endocytosis](https://reactome.org/content/detail/R-HSA-8856828) | curated |
| [Developmental Lineage of Mammary Gland Myoepithelial Cells](https://reactome.org/content/detail/R-HSA-9927432) | curated |
| [Downregulation of ERBB2 signaling](https://reactome.org/content/detail/R-HSA-8863795) | curated |
| [EGFR Transactivation by Gastrin](https://reactome.org/content/detail/R-HSA-2179392) | curated |
| [EGFR downregulation](https://reactome.org/content/detail/R-HSA-182971) | curated |
| [EGFR interacts with phospholipase C-gamma](https://reactome.org/content/detail/R-HSA-212718) | curated |
| [ERBB2 Activates PTK6 Signaling](https://reactome.org/content/detail/R-HSA-8847993) | curated |
| [ERBB2 Regulates Cell Motility](https://reactome.org/content/detail/R-HSA-6785631) | curated |
| [Estrogen-dependent nuclear events downstream of ESR-membrane signaling](https://reactome.org/content/detail/R-HSA-9634638) | curated |
| [Extra-nuclear estrogen signaling](https://reactome.org/content/detail/R-HSA-9009391) | curated |
| [GAB1 signalosome](https://reactome.org/content/detail/R-HSA-180292) | curated |
| [GRB2 events in EGFR signaling](https://reactome.org/content/detail/R-HSA-179812) | curated |
| [NOTCH3 Activation and Transmission of Signal to the Nucleus](https://reactome.org/content/detail/R-HSA-9013507) | curated |
| [PI3K events in ERBB2 signaling](https://reactome.org/content/detail/R-HSA-1963642) | curated |
| [PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling](https://reactome.org/content/detail/R-HSA-6811558) | curated |
| [PIP3 activates AKT signaling](https://reactome.org/content/detail/R-HSA-1257604) | curated |
| [PTK6 promotes HIF1A stabilization](https://reactome.org/content/detail/R-HSA-8857538) | curated |
| [RAF/MAP kinase cascade](https://reactome.org/content/detail/R-HSA-5673001) | curated |
| [SHC1 events in EGFR signaling](https://reactome.org/content/detail/R-HSA-180336) | curated |
| [Signal transduction by L1](https://reactome.org/content/detail/R-HSA-445144) | curated |
| [Signaling by EGFR](https://reactome.org/content/detail/R-HSA-177929) | curated |
| [Signaling by ERBB2](https://reactome.org/content/detail/R-HSA-1227986) | curated |
| [Signaling by ERBB4](https://reactome.org/content/detail/R-HSA-1236394) | curated |
| [TFAP2 (AP-2) family regulates transcription of growth factors and their receptors](https://reactome.org/content/detail/R-HSA-8866910) | curated |
| [GRB2 events in ERBB2 signaling](https://reactome.org/content/detail/R-HSA-1963640) | electronic |
| [PLCG1 events in ERBB2 signaling](https://reactome.org/content/detail/R-HSA-1251932) | electronic |
| [SHC1 events in ERBB2 signaling](https://reactome.org/content/detail/R-HSA-1250196) | electronic |

### Molecular function & processes (GO — experimentally supported) {#go}

**Molecular function:** chromatin binding, protein tyrosine kinase activity, transmembrane signaling receptor activity, epidermal growth factor receptor activity, enzyme binding, kinase binding.

**Biological process:** positive regulation of protein phosphorylation, signal transduction, cell surface receptor signaling pathway, epidermal growth factor receptor signaling pathway, positive regulation of cell population proliferation, positive regulation of cell growth.

## Clinical significance {#significance}

**Benign/Likely benign** — review status Multiple submitters *(criteria provided, multiple submitters, no conflicts)*, last evaluated 2026-01-19.

**Submitter consensus:** conflicting (2 Likely benign, 1 not provided, 1 Benign).

**Submission history:** 4 submissions (2024–2026); classifications have differed over time.

### Submitter classifications {#submitters}

| Submitter | Classification | Review | Method | Date |
| --- | --- | --- | --- | --- |
| Laboratory of Translational Genomics,  National Cancer Institute | not provided | no classification provided | not provided |  |
| Myriad Genetics, Inc. | Benign | criteria provided, single submitter | clinical testing | 2024-10-17 |
| Labcorp Genetics (formerly Invitae), Labcorp | Likely benign | criteria provided, single submitter | clinical testing | 2026-01-19 |
| Ambry Genetics | Likely benign | criteria provided, single submitter | clinical testing | 2024-10-15 |

## Associated conditions {#conditions}

[lung cancer](https://sugi.bio/atlas/disease/lung-cancer/), [endometrial carcinoma](https://sugi.bio/atlas/disease/endometrial-carcinoma/), [hereditary neoplastic syndrome](https://sugi.bio/atlas/disease/hereditary-neoplastic-syndrome/).

**Reported phenotype names (ClinVar):** Lung cancer, Endometrial carcinoma, EGFR-related lung cancer, Hereditary cancer-predisposing syndrome, Lung cancer, somatic, Malignant tumor of lung, Tumor predisposition, Hereditary neoplastic syndrome, Neoplastic Syndromes, Hereditary, Hereditary Cancer Syndrome.

## Similar variants {#similar}

Related EGFR variant pages (same residue, condition, or type): [EGFR p.Pro848Ser](/variant/egfr-p-pro848ser), [EGFR p.Pro848Leu](/variant/egfr-p-pro848leu), [EGFR p.Pro848Gln](/variant/egfr-p-pro848gln), [EGFR c.1207+5G>A](/variant/egfr-c-1207-plus-5g-a), [EGFR c.1298+3A>G](/variant/egfr-c-1298-plus-3a-g), [EGFR c.1298+4A>G](/variant/egfr-c-1298-plus-4a-g), [EGFR c.1298+6T>C](/variant/egfr-c-1298-plus-6t-c), [EGFR c.1499-3C>T](/variant/egfr-c-1499-minus-3c-t).

### Data sources & attribution {#sources}

ClinVar (NCBI — public domain, built 2026-10-11); gnomAD v4.1 (Broad Institute, built 2026-10-06); AlphaMissense (Cheng et al. 2023, © Google DeepMind — CC BY 4.0, built 2026-01-27); REVEL (Ioannidis et al. 2016 — ODbL, built 2026-07-13); SaProt (Su et al. 2023 — MIT, built 2026-07-14); SpliceAI (Illumina — free for non-commercial use, built 2026-10-13); CADD (Rentzsch et al. 2019, University of Washington — free for non-commercial use, built 2026-10-10); Conservation (phyloP/phastCons/GERP) (UCSC hg38 470-way mammal (Hiller Lab) + Ensembl Compara, built 2026-07-12); gnomAD Non-coding Constraint (Gnocchi) (Chen et al. 2024, Broad Institute — CC0, built 2026-10-11); gnomAD Regional Missense Constraint (Broad Institute — CC0, built 2026-10-13); Pangolin (Zeng & Li 2022 — CC BY 4.0, built 2026-10-11); Repeat regions (UCSC — RepeatMasker, TRF, segmental duplications, built 2026-10-11); ClinGen (ClinGen, built 2026-09-22); UniProt (CC BY 4.0); Reactome / GO (CC BY 4.0, built 2026-09-23); MaveDB (per-record license, built 2026-10-11); CIViC (CC0, built 2026-09-22); Orphanet (Orphanet, built 2026-06-12)

*Primary record: NCBI ClinVar (variation 132949). Classifications reflect these databases as of the page's build date and may change. Free reference use — not medical advice; consult the primary submitters and a clinician.*